Viveve Medical, Inc. (VIVE)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2021 | -20.61 Million USD | -9.76% |
| 2020 | -18.49 Million USD | 35.04% |
| 2019 | -30.67 Million USD | 35.69% |
| 2018 | -44.16 Million USD | -33.55% |
| 2017 | -33.34 Million USD | -80.01% |
| 2016 | -18.63 Million USD | -56.0% |
| 2015 | -11.93 Million USD | -115.76% |
| 2014 | -5.66 Million USD | -19.48% |
| 2013 | -4.65 Million USD | -13.94% |
| 2012 | -4.08 Million USD | -23.21% |
| 2011 | -3.31 Million USD | -402.73% |
| 2010 | -3.06 Million USD | 57.1% |
| 2009 | -1.53 Million USD | 25.55% |
| 2008 | -1.96 Million USD | 33.96% |
| 2007 | -2.69 Million USD | -271.02% |
| 2006 | 908 Thousand USD | 48.15% |
| 2005 | -1.37 Million USD | -61.11% |
| 2004 | -833 Thousand USD | -197.58% |
| 2003 | 714 Thousand USD | 180.71% |
| 2002 | 231 Thousand USD | 110.51% |
| 2001 | -3.5 Million USD | 23.16% |
| 2000 | -4.16 Million USD | 0.96% |
| 1999 | -4.38 Million USD | 68.06% |
| 1998 | -13.9 Million USD | -12.5% |
| 1997 | -12.55 Million USD | -884.62% |
| 1996 | -800 Thousand USD | -192.86% |
| 1995 | 2 Million USD | 148.28% |
| 1994 | -2.5 Million USD | 30.95% |
| 1993 | -3.9 Million USD | -119.35% |
| 1992 | -3.1 Million USD | 1650.0% |
| 1991 | -1.8 Million USD | -1700.0% |
| 1990 | -100 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 Q3 | -4.51 Million USD | 7.43% |
| 2022 Q2 | -4.87 Million USD | 7.9% |
| 2022 Q1 | -5.29 Million USD | 8.06% |
| 2021 Q2 | -4.67 Million USD | 3.97% |
| 2021 Q3 | -5.32 Million USD | -13.93% |
| 2021 Q4 | -5.75 Million USD | -8.08% |
| 2021 FY | - USD | -9.76% |
| 2021 Q1 | -4.86 Million USD | -17.99% |
| 2020 Q3 | -3.13 Million USD | 32.48% |
| 2020 Q1 | -5.59 Million USD | 16.84% |
| 2020 Q2 | -4.64 Million USD | 16.99% |
| 2020 Q4 | -4.12 Million USD | -31.63% |
| 2020 FY | - USD | 35.04% |
| 2019 Q3 | -6.3 Million USD | 22.71% |
| 2019 Q1 | -8.04 Million USD | 34.41% |
| 2019 Q4 | -6.72 Million USD | -6.56% |
| 2019 Q2 | -8.16 Million USD | -1.43% |
| 2019 FY | - USD | 35.69% |
| 2018 Q3 | -10.85 Million USD | -7.32% |
| 2018 Q1 | -11.2 Million USD | -18.92% |
| 2018 Q2 | -10.11 Million USD | 9.72% |
| 2018 FY | - USD | -33.55% |
| 2018 Q4 | -12.26 Million USD | -13.06% |
| 2017 Q1 | -6.29 Million USD | -13.82% |
| 2017 FY | - USD | -80.01% |
| 2017 Q4 | -9.41 Million USD | -8.55% |
| 2017 Q3 | -8.67 Million USD | 3.22% |
| 2017 Q2 | -8.96 Million USD | -42.46% |
| 2016 Q3 | -4.6 Million USD | -1.81% |
| 2016 Q4 | -5.52 Million USD | -20.14% |
| 2016 Q1 | -3.97 Million USD | -11.53% |
| 2016 Q2 | -4.52 Million USD | -13.71% |
| 2016 FY | - USD | -56.0% |
| 2015 Q2 | -2.88 Million USD | -18.89% |
| 2015 Q3 | -3.08 Million USD | -7.01% |
| 2015 Q1 | -2.42 Million USD | -47.05% |
| 2015 FY | - USD | -115.76% |
| 2015 Q4 | -3.56 Million USD | -15.56% |
| 2014 Q3 | -2.33 Million USD | -97.77% |
| 2014 FY | - USD | -19.48% |
| 2014 Q1 | -960 Thousand USD | 9.86% |
| 2014 Q2 | -1.18 Million USD | -22.92% |
| 2014 Q4 | -1.64 Million USD | 29.36% |
| 2013 Q3 | -1.25 Million USD | 1.18% |
| 2013 Q1 | -1.05 Million USD | -19.25% |
| 2013 FY | - USD | -13.94% |
| 2013 Q4 | -1.06 Million USD | 15.27% |
| 2013 Q2 | -1.27 Million USD | -20.8% |
| 2012 Q3 | -1.08 Million USD | -13.63% |
| 2012 Q2 | -954 Thousand USD | 17.83% |
| 2012 Q1 | -1.16 Million USD | 71.79% |
| 2012 FY | - USD | -23.21% |
| 2012 Q4 | -883 Thousand USD | 18.54% |
| 2011 Q4 | -4.11 Million USD | -174.22% |
| 2011 FY | - USD | -402.73% |
| 2011 Q2 | -1.21 Million USD | -150.14% |
| 2011 Q1 | 2.41 Million USD | 1281.14% |
| 2011 Q3 | -1.5 Million USD | -23.84% |
| 2010 FY | - USD | 57.1% |
| 2010 Q3 | -5000.00 USD | 98.7% |
| 2010 Q1 | -548 Thousand USD | 5.84% |
| 2010 Q2 | -384 Thousand USD | 29.93% |
| 2010 Q4 | 175 Thousand USD | 3600.0% |
| 2009 Q3 | -337 Thousand USD | -18.66% |
| 2009 Q1 | -333 Thousand USD | -89.2% |
| 2009 Q4 | -582 Thousand USD | -72.7% |
| 2009 FY | - USD | 25.55% |
| 2009 Q2 | -284 Thousand USD | 14.71% |
| 2008 Q1 | -843 Thousand USD | 13.89% |
| 2008 FY | - USD | 33.96% |
| 2008 Q4 | -176 Thousand USD | 49.43% |
| 2008 Q3 | -348 Thousand USD | 50.0% |
| 2008 Q2 | -696 Thousand USD | 17.44% |
| 2007 FY | - USD | -271.02% |
| 2007 Q4 | -979 Thousand USD | -44.4% |
| 2007 Q2 | -564 Thousand USD | 37.54% |
| 2007 Q1 | -903 Thousand USD | -464.38% |
| 2007 Q3 | -678 Thousand USD | -20.21% |
| 2006 Q2 | -131 Thousand USD | 47.39% |
| 2006 FY | - USD | 48.15% |
| 2006 Q1 | -249 Thousand USD | 48.45% |
| 2006 Q4 | -160 Thousand USD | 47.02% |
| 2006 Q3 | -302 Thousand USD | -130.53% |
| 2005 FY | - USD | -61.11% |
| 2005 Q4 | -483 Thousand USD | 3.98% |
| 2005 Q3 | -503 Thousand USD | -31.33% |
| 2005 Q1 | -255 Thousand USD | -240.11% |
| 2005 Q2 | -383 Thousand USD | -50.2% |
| 2004 Q3 | -444 Thousand USD | -21.64% |
| 2004 Q2 | -365 Thousand USD | 4.2% |
| 2004 Q1 | -381 Thousand USD | -166.61% |
| 2004 FY | - USD | -197.58% |
| 2004 Q4 | 182 Thousand USD | 140.99% |
| 2003 Q2 | 192 Thousand USD | 1164.71% |
| 2003 FY | - USD | 180.71% |
| 2003 Q3 | 217 Thousand USD | 6.51% |
| 2003 Q4 | 337 Thousand USD | 149.78% |
| 2003 Q1 | 36 Thousand USD | -91.54% |
| 2002 Q4 | 230 Thousand USD | -15.55% |
| 2002 FY | - USD | 110.51% |
| 2002 Q3 | 204 Thousand USD | 48.75% |
| 2002 Q2 | 120 Thousand USD | 169.26% |
| 2002 Q1 | -231 Thousand USD | 24.51% |
| 2001 Q4 | -279 Thousand USD | 67.55% |
| 2001 Q3 | -943 Thousand USD | 10.53% |
| 2001 Q2 | -1.05 Million USD | 11.95% |
| 2001 Q1 | -1.09 Million USD | -2.31% |
| 2001 FY | - USD | 23.16% |
| 2000 Q1 | -1.65 Million USD | -485.28% |
| 2000 Q2 | -558 Thousand USD | 61.54% |
| 2000 Q3 | -845 Thousand USD | -42.94% |
| 2000 Q4 | -1.1 Million USD | -21.62% |
| 2000 FY | - USD | 0.96% |
| 1999 Q4 | -288 Thousand USD | 77.0% |
| 1999 Q3 | -1.3 Million USD | 18.75% |
| 1999 Q2 | -1.5 Million USD | -6.67% |
| 1999 Q1 | -1.5 Million USD | 31.82% |
| 1999 FY | - USD | 68.06% |
| 1998 Q1 | -3.5 Million USD | 15.91% |
| 1998 Q3 | -3.4 Million USD | 33.33% |
| 1998 Q4 | -2 Million USD | 35.29% |
| 1998 FY | - USD | -12.5% |
| 1998 Q2 | -4.9 Million USD | -37.84% |
| 1997 Q2 | -2.3 Million USD | 17.86% |
| 1997 Q3 | -3.1 Million USD | -43.48% |
| 1997 FY | - USD | -884.62% |
| 1997 Q1 | -2.7 Million USD | -115.38% |
| 1997 Q4 | -4.5 Million USD | -33.33% |
| 1996 Q1 | 1.3 Million USD | 126.67% |
| 1996 Q4 | -1.2 Million USD | -225.0% |
| 1996 Q3 | -300 Thousand USD | 63.64% |
| 1996 Q2 | -900 Thousand USD | -191.67% |
| 1996 FY | - USD | -192.86% |
| 1995 Q2 | 1.5 Million USD | -48.28% |
| 1995 Q3 | 1.6 Million USD | 6.67% |
| 1995 Q4 | -4.5 Million USD | -381.25% |
| 1995 Q1 | 2.9 Million USD | 583.33% |
| 1995 FY | - USD | 148.28% |
| 1994 Q1 | -600 Thousand USD | 50.0% |
| 1994 FY | - USD | 30.95% |
| 1994 Q3 | -1 Million USD | -83.33% |
| 1994 Q4 | -400 Thousand USD | 45.45% |
| 1994 Q2 | -600 Thousand USD | 0.0% |
| 1993 Q4 | -1 Million USD | -33.33% |
| 1993 FY | - USD | -119.35% |
| 1993 Q1 | -800 Thousand USD | 20.0% |
| 1993 Q2 | -1.2 Million USD | -50.0% |
| 1993 Q3 | -900 Thousand USD | 25.0% |
| 1992 Q4 | -1 Million USD | -900.0% |
| 1992 Q1 | 23.5 Million USD | 1275.0% |
| 1992 Q3 | -500 Thousand USD | 88.89% |
| 1992 Q2 | -900 Thousand USD | -103.83% |
| 1992 FY | - USD | 1650.0% |
| 1991 Q4 | -2 Million USD | -2100.0% |
| 1991 Q2 | 100 Thousand USD | 0.0% |
| 1991 Q3 | 100 Thousand USD | 0.0% |
| 1991 Q1 | 100 Thousand USD | 200.0% |
| 1991 FY | - USD | -1300.0% |
| 1990 FY | - USD | 0.0% |
| 1990 Q3 | 100 Thousand USD | 0.0% |
| 1990 Q2 | 100 Thousand USD | 0.0% |
| 1990 Q1 | 100 Thousand USD | 0.0% |
| 1990 Q4 | -100 Thousand USD | -200.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acutus Medical, Inc. | -13.48 Million USD | -52.866% |
| Biotricity, Inc. | -8.82 Million USD | -133.534% |
| Cell MedX Corp. | - USD | Infinity% |
| Dynatronics Corporation | -976 Thousand USD | -2012.38% |
| Nemaura Medical Inc. | -7.28 Million USD | -182.926% |
| PetVivo Holdings, Inc. | -10.49 Million USD | -96.455% |
| RetinalGenix Technologies Inc. | -2.08 Million USD | -887.901% |
| Sonendo, Inc. | -54.76 Million USD | 62.356% |
| Telesis Bio, Inc. | -40.49 Million USD | 49.085% |
| Talis Biomedical Corporation | -66.04 Million USD | 68.783% |